Jazz Pharmaceuticals
Corporate brand
UnclaimedA global biopharmaceutical company focused on medicines for sleep disorders, serious neurological conditions, and cancer.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Jazz Pharmaceuticals is a global biopharmaceutical company whose principal activities are the discovery, development, acquisition, and commercialization of medicines for serious and underserved medical conditions. The company is particularly associated with sleep medicine and specialty pharmaceuticals, while also maintaining a substantial oncology portfolio. Its marketed products and development programs have addressed narcolepsy, idiopathic hypersomnia, cataplexy, excessive daytime sleepiness, acute lymphoblastic leukemia, acute myeloid leukemia, small-cell lung cancer, and other serious diseases. The company was established in 2003 and initially built its business around specialty medicines and products addressing unmet needs. A major turning point came through the acquisition of Azur Pharma in 2012, which expanded Jazz's international commercial infrastructure and broadened its portfolio. Jazz subsequently used acquisitions, licensing arrangements, internal development, and regulatory expansion to strengthen its position in sleep medicine and oncology. The acquisition of Celator Pharmaceuticals in 2016 brought Vyxeos, a liposomal formulation for certain adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes. The acquisition of GW Pharmaceuticals in 2021 added Epidiolex, a cannabidiol-based medicine for certain severe childhood epilepsies, and materially expanded Jazz's neuroscience franchise. Sleep medicine remains central to the company's identity. Xyrem, an oral sodium oxybate product, became an important treatment for narcolepsy-related cataplexy and excessive daytime sleepiness. Jazz later developed and commercialized Xywav, a lower-sodium oxybate formulation for narcolepsy and idiopathic hypersomnia. Sunosi, a wake-promoting medicine, and other sleep-focused products complement the oxybate franchise. Because some of these medicines contain controlled substances or require special distribution and risk-management systems, Jazz operates within extensive regulatory, prescribing, pharmacy, and patient-support requirements. In oncology, Jazz has commercialized or developed medicines including Vyxeos, Rylaze, Zepzelca, and other products obtained through acquisitions or partnerships. The oncology business has focused on hematologic malignancies and selected solid tumors, while the broader corporate strategy has emphasized specialized markets where clinical expertise, regulatory capabilities, and targeted commercial infrastructure can create value. Jazz is incorporated in Ireland and has historically maintained major corporate operations in the United States. Its shares trade on Nasdaq under the ticker JAZZ. The company sells products directly or through regional arrangements in the United States and international markets. Its stated mission is to improve patients' lives by identifying, developing, and commercializing medicines that address unmet medical needs. The business is exposed to the normal risks of specialty pharmaceuticals, including clinical-development failure, regulatory decisions, patent and exclusivity disputes, competition from generics or alternative therapies, pricing pressure, product-safety obligations, and reliance on a limited number of commercially important products.
History
Jazz Pharmaceuticals was founded in 2003 as a specialty pharmaceutical company. Its early strategy centered on acquiring, developing, and commercializing medicines for conditions with significant unmet medical needs rather than building a broad primary-care portfolio. The company became publicly traded and developed a business model based on focused therapeutic franchises, regulatory expertise, and specialized distribution. A major expansion occurred in 2012, when Jazz acquired Azur Pharma. Azur brought international operations and additional specialty products, helping Jazz evolve from a smaller specialty-pharmaceutical business into a company with a broader geographic and commercial footprint. The combined organization retained the Jazz Pharmaceuticals identity and continued to focus on products that could be supported by specialized commercial capabilities. Sleep medicine became the company's most recognizable area. Xyrem, a sodium oxybate product, was commercialized for narcolepsy-related cataplexy and excessive daytime sleepiness. Its controlled-substance status required a restricted distribution and risk-management framework. Jazz subsequently developed Xywav, which contains less sodium than Xyrem and received United States approval in 2020 for narcolepsy-related indications. The company later obtained approval for Xywav in idiopathic hypersomnia, extending the product into another serious sleep disorder. Sunosi added a different pharmacological approach for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Jazz also expanded into oncology through acquisitions and product development. In 2016, it acquired Celator Pharmaceuticals, obtaining Vyxeos, a liposomal combination of daunorubicin and cytarabine for particular adult AML populations. The product gave Jazz an important foothold in hematologic oncology. Subsequent oncology additions included Rylaze, an asparaginase product for acute lymphoblastic leukemia or lymphoblastic lymphoma, and Zepzelca, a medicine for metastatic small-cell lung cancer after progression on platinum-containing chemotherapy. Jazz's oncology strategy has combined owned products, acquired assets, and development partnerships. In 2021, Jazz completed its acquisition of GW Pharmaceuticals. The transaction added Epidiolex, a purified cannabidiol oral solution approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in appropriate patients. It also gave Jazz GW's development capabilities and experience in cannabinoid-derived medicines. The deal significantly broadened Jazz's neuroscience platform beyond sleep disorders and made the company a larger international specialty biopharmaceutical business. Jazz's corporate structure is based in Ireland, while the United States remains a major commercial and operating market. The company sells products in the United States and internationally, using direct commercial operations and regional arrangements where appropriate. Its portfolio remains concentrated in areas where diseases are serious, patient populations may be relatively specialized, and treatment requires medical, regulatory, or distribution expertise. The company's continuing challenges include maintaining exclusivity for important products, managing controlled-substance distribution requirements, demonstrating clinical benefit for new indications, responding to generic and branded competition, and integrating acquired assets. Jazz's current identity is therefore the result of both organic product development and a sustained acquisition strategy, with neuroscience, sleep medicine, and oncology as its principal strategic pillars.
- 2023
Xywav receives an idiopathic-hypersomnia indication
[6]The FDA approves Xywav for adults with idiopathic hypersomnia, extending Jazz's sleep-medicine franchise.
- 2021
GW Pharmaceuticals acquisition closes
[7]Jazz completes the acquisition of GW Pharmaceuticals, adding Epidiolex and expanding its neuroscience platform.
- 2020
Xywav receives United States approval
[5]The FDA approves Xywav for cataplexy or excessive daytime sleepiness in patients with narcolepsy.
- 2016
Celator acquisition adds Vyxeos
[4]Jazz acquires Celator Pharmaceuticals and obtains Vyxeos, strengthening its oncology business.
- 2012
Azur Pharma acquisition
[4]Jazz acquires Azur Pharma, broadening its international commercial platform and specialty-medicine portfolio.
- 2003
Jazz Pharmaceuticals is founded
[2]Jazz Pharmaceuticals begins operations as a specialty pharmaceutical company focused on medicines for unmet medical needs.
Products and positioning
A specialty biopharmaceutical company concentrating on neuroscience, sleep medicine, and oncology, with an emphasis on serious conditions and markets in which focused clinical and commercial expertise can address unmet needs.
Sleep medicine · 2020
Xywav
Xywav is an oral oxybate formulation containing calcium, magnesium, potassium, and sodium oxybates. In the United States it is approved for cataplexy or excessive daytime sleepiness in narcolepsy and for idiopathic hypersomnia in adults. It is distributed under a restricted system because of risks associated with oxybate and central nervous system depressants.
Sleep medicine
Xyrem
Xyrem is an oral sodium oxybate medicine used in the United States to treat cataplexy or excessive daytime sleepiness in patients with narcolepsy. It became one of Jazz's foundational products and helped establish the company's specialized sleep-medicine infrastructure, including controlled distribution and patient-support systems.
Neuroscience · 2018
Epidiolex
Epidiolex is an oral solution containing purified cannabidiol. In the United States it is approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients meeting the applicable labeling criteria. The product entered Jazz's portfolio through the acquisition of GW Pharmaceuticals.
Sleep medicine · 2019
Sunosi
Sunosi is a wake-promoting medicine approved in the United States to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. It complements Jazz's oxybate products by addressing excessive sleepiness through a different pharmacological approach.
Hematologic oncology · 2017
Vyxeos
Vyxeos is a liposomal formulation combining daunorubicin and cytarabine. It is approved for certain adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes. Jazz obtained the product through its acquisition of Celator Pharmaceuticals.
Hematologic oncology · 2021
Rylaze
Rylaze is an asparagine-specific enzyme used as part of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia or lymphoblastic lymphoma in patients who have developed hypersensitivity to an Escherichia coli-derived asparaginase. Its development addressed the need for an alternative formulation with more predictable dosing intervals.
Solid-tumor oncology · 2020
Zepzelca
Zepzelca is an intravenous medicine approved in the United States through an accelerated pathway for adults with metastatic small-cell lung cancer whose disease has progressed on or after platinum-containing chemotherapy. Its continued regulatory position is subject to the requirements associated with accelerated approval.
Brand decisions
2021
Acquisition of GW PharmaceuticalsM&ABackground
Jazz wanted to expand its neuroscience business and diversify beyond sleep medicine.
Action taken
Jazz completed the acquisition of GW Pharmaceuticals, obtaining Epidiolex and GW's cannabinoid-derived medicine expertise.
Aftermath
The transaction materially expanded Jazz's neuroscience platform and international operations.
2016
Acquisition of Celator PharmaceuticalsM&ABackground
Jazz aimed to build a more substantial oncology franchise, particularly in hematologic malignancies.
Action taken
Jazz acquired Celator Pharmaceuticals and its lead product, Vyxeos.
Aftermath
The deal added an approved oncology product and increased Jazz's presence in hospital-based cancer care.
2012
Acquisition of Azur PharmaM&ABackground
Jazz sought to expand beyond its original specialty-pharmaceutical base and increase its international reach.
Action taken
Jazz acquired Azur Pharma and combined the businesses under the Jazz Pharmaceuticals identity.
Aftermath
The transaction broadened Jazz's geographic footprint and product portfolio.
Recent events
Reported
Setara launches with $90 million in Series A financing[8]
Setara launched with $90 million in Series A financing. Jazz Pharmaceuticals joined as a new shareholder following its acquisition of Actio Biosciences.
Reported
FDA approves Xywav for idiopathic hypersomnia in adults[9]
The FDA approved a new indication for Xywav to manage idiopathic hypersomnia in adults.
Reported
Onera Health closes €10.5 million Series B funding round[10]
Onera Health closed a €10.5 million Series B funding round led by Innovation Industries in collaboration with Invest-NL and existing investors. The company said it intends to use the funds for clinical studies and to further commercialize its sleep diagnostics and monitoring products in Europe and the United States.
Reported
Jazz Pharmaceuticals completes acquisition of GW Pharmaceuticals[11]
Jazz Pharmaceuticals announced that it completed its acquisition of GW Pharmaceuticals.
Reported
Bionical Emas announces managed access program for JZP-458[12]
Bionical Emas announced a Managed Access Program for Jazz Pharmaceuticals' medicinal product JZP-458, initially launching in select countries within Europe.
Jazz Pharmaceuticals announces acquisition of GW Pharmaceuticals[13]
Jazz Pharmaceuticals and GW Pharmaceuticals announced a definitive agreement for Jazz to acquire GW for $220 per American Depositary Share, in a transaction valued at $7.2 billion. The transaction was subject to shareholder, court and regulatory approvals and was expected to close in the second quarter of 2021.
- Unconfirmed
Reported
FDA grants accelerated approval for Zepzelca[14]
The FDA granted accelerated approval for Zepzelca (lurbinectedin) to treat adults with metastatic small cell lung cancer whose disease progressed on or after platinum-based chemotherapy. Jazz Pharmaceuticals and PharmaMar secured the approval.
Sources14 sources
- 1Jazz Pharmaceuticals official websitejazzpharma.com
- 2Jazz Pharmaceuticals: Aboutjazzpharma.com
- 3Jazz Pharmaceuticals: Productsjazzpharma.com
- 4Jazz Pharmaceuticals: Newsjazzpharma.com
- 5FDA approval of Xywav for narcolepsyfda.gov
- 6FDA approval of Xywav for idiopathic hypersomniafda.gov
- 7GW Pharmaceuticals acquisition closesjazzpharma.com
- 8Setara获9000万美元A轮融资并启动运营bioxconomy.com
- 9FDA 批准 Xywav 用于治疗成人特发性嗜睡症healio.com
- 10Onera Health完成1050万欧元B轮融资finanznachrichten.de
- 11Jazz Pharmaceuticals完成对GW Pharmaceuticals的收购prnewswire.com
- 12Bionical Emas宣布推出JZP-458管理式用药计划europapress.es
- 13Jazz Pharmaceuticals 宣布收购 GW Pharmaceuticalsnewcannabisventures.com
- 14FDA加速批准Zepzelcapharmaceutical-business-review.com
Cite this profile: Cite the canonical profile. /brand-wiki/jazz-pharmaceuticals-united-states · Editorial policy · How profiles are compiled